Evolus, Inc. 8-K

What Happened

• Evolus filed a Form 8-K on May 4, 2026, furnishing a press release announcing its financial results for the quarter ended March 31, 2026 (press release dated May 4, 2026).
• Separately, on May 1, 2026, Evolus terminated its Sales Agreement (originally dated March 8, 2023) with SVB Securities LLC (now Leerink Partners LLC), which had authorized at‑the‑market (ATM) sales of up to $50.0 million of common stock. The company had not sold any shares under that agreement prior to termination. The press release is included as Exhibit 99.1 to the filing. The Form 8-K was signed by David Moatazedi, President and CEO.

Key Details

• Filing date: May 4, 2026; quarter reported: ended March 31, 2026.
• ATM program: Sales Agreement dated March 8, 2023 (agent: SVB Securities LLC / Leerink Partners LLC), capacity $50.0 million.
• Termination date of Sales Agreement: May 1, 2026; no shares sold under the program before termination.
• Press release announcing results furnished as Exhibit 99.1 to the 8-K.

Why It Matters

• The earnings press release contains the company’s latest quarterly financials (revenue, earnings, guidance details) that can directly affect the stock price and investor outlook—investors should read the press release for the specific numbers and metrics.
• Ending the $50.0M ATM program removes an existing mechanism for issuing shares continuously into the market; because no shares were sold under it, there is no immediate dilution, but it does reduce a near‑term capital‑raising option.
• No management changes or other material transactions were reported in this filing; investors should monitor subsequent disclosures for the company’s capital plan or new financing arrangements.